Skip to main content
. 2020 Jul 11;20:276. doi: 10.1186/s12883-020-01858-2

Table 1.

Demographic and clinical data of people with Parkinson’s disease and controls

All PwPD
(n = 30)
BIG
(n = 11)
Controls
(n = 15)
Age (years) 64.8 ± 7.3 69.8 ± 6.1 65.0 ± 5.6
Sex (female/male) 10/20 3/8 10/5
LED (mg) 614 ± 394 518 ± 295 $ N/A
FD (years) 4.6 ± 3.9 3.6 ± 2.5 N/A
UPDRS III (at baseline) a 18 [12 to 24] 23 [12 to 25] N/A
Handedness (right/ ambidextrous/left) 26/4/0 8/3/0 15/0/0
PANDA (normal/MCI/ dementia likely) 24/2/4 8/1/2 14/1/0
FAB (frontal impair-ment: yes/no) 0/30 0/11 0/15

PwPD people with Parkinson’s disease, LED Levodopa Equivalent Dose ($ no significant LED change over the time period of investigation), FD first diagnosis, UPDRS III motor subscale of the MDS Unified Parkinson’s Disease Rating Scale, PANDA Parkinson Neuropsychometric Dementia Assessment, MCI mild cognitive impairment, FAB Frontal Assessment Battery, N/A not applicable

a = given as median (range)